Alpha-1 antitrypsin deficiency (AATD)
Conditions
Brief summary
The proportion of participants with adverse events.
Detailed description
Single Ascending Dose - Change from baseline in levels of serum M-AAT protein., Multiple Ascending Dose - Change from baseline in levels of serum M-AAT protein, Single Ascending Dose - Area under the plasma concentration time curve for WVE-006 from time of dosing to the last measurable concentration (AUClast), Single Ascending Dose - Maximum concentration of WVE-006 in plasma, Multiple Ascending Doses - Area under the plasma concentration time curve for WVE-006 from time of dosing to the last measurable concentration (AUClast), Multiple Ascending Doses - Maximum concentration of WVE-006 in plasma (Cmax)
Interventions
DRUGWVE-006
Sponsors
Wave Life Sciences Ireland Limited
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The proportion of participants with adverse events. | — |
Secondary
| Measure | Time frame |
|---|---|
| Single Ascending Dose - Change from baseline in levels of serum M-AAT protein., Multiple Ascending Dose - Change from baseline in levels of serum M-AAT protein, Single Ascending Dose - Area under the plasma concentration time curve for WVE-006 from time of dosing to the last measurable concentration (AUClast), Single Ascending Dose - Maximum concentration of WVE-006 in plasma, Multiple Ascending Doses - Area under the plasma concentration time curve for WVE-006 from time of dosing to the last measurable concentration (AUClast), Multiple Ascending Doses - Maximum concentration of WVE-006 in plasma (Cmax) | — |
Countries
Finland, Germany
Outcome results
None listed